Skip to main content
. 2021 Nov 5;60(49):25966–25972. doi: 10.1002/anie.202110702

Figure 7.

Figure 7

Multiplex Simoa neutralization assay for the SARS‐CoV‐2 wild‐type, Alpha, Beta, and Delta variants. A) Comparison of singleplex and multiplex Simoa assays using increasing concentrations of a SARS‐CoV‐2 neutralizing antibody (40591‐MM43). B) NT50 for the SARS‐CoV‐2 wild‐type, Alpha, Beta, and Delta variants in pre‐pandemic controls, COVID‐19 patients and vaccinated subjects. C) NT50 for each subject in the COVID‐19 and vaccinated groups.